Searchable abstracts of presentations at key conferences in endocrinology

ea0034p272 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Liver fibrosis is common in Alstrom syndrome and can be identified using non-invasive tests

Hazlehurst Jonathan , Armstrong Matthew , Hodgkiss Jayne , Crowley Rachel , Geberhiwot Tarekegn , Newsome Phillip , Tomlinson Jeremy

Alstrom syndrome is an autosomal recessive ciliopathy that is characterised by increased body mass index, type 2 diabetes, retinal dystrophy, sensorineural hearing loss, cardiac fibrosis, and chronic kidney disease. Non-alcoholic fatty liver disease (NAFLD) in Alstrom patients ranges from simple steatosis, steatohepatitis and ultimately to fibrosis and cirrhosis. Nafld fibrosis score (http://nalfdscore.com/), enhanced liver fibrosis (ELF)-panel blood tests and Fibroscans are n...

ea0028oc4.7 | Steroid | SFEBES2012

Glucocorticoids increase subcutaneous adipose tissue insulin sensitivity in vivo: a randomised double-blind, placebo controlled, cross over study

Hazlehurst Jonathan , Armstrong Matthew , Borrows Sarah , Gathercole Laura , Stewart Paul , Tomlinson Jeremy

Glucocorticoid (GC) excess, Cushing’s syndrome, is characterized by central obesity, proximal myopathy, insulin resistance and potentially type 2 diabetes mellitus. Current dogma dictates that GCs cause insulin resistance across all tissues. We have previously demonstrated that GCs cause insulin sensitization of human adipose tissue in vitro, whilst inducing insulin resistance in human skeletal muscle. No prior study has evaluated whether these observations transla...

ea0028p48 | Clinical practice/governance and case reports | SFEBES2012

A comparative quality assessment of evidence-based clinical guidelines in Endocrinology

Hazlehurst Jonathan , Armstrong Matthew , Sherlock Mark , O'Reilly Mick , Rowe Ian , Franklyn Jayne , Stewart Paul , Tomlinson Jeremy

Evidence-based clinical guidelines in Endocrinology attempt to improve and standardise patient care. There has been an expansion in guideline production although some of the heterogeneous methods used to assess the underlying evidence base may limit interpretation and implementation. Current and archived guidelines from The American Association of Clinical Endocrinologists (AACE), The Endocrine Society (ES), The American Thyroid Association, The British Thyroid Association and...

ea0038oc2.1 | Translational pathophysiology and therapeutics | SFEBES2015

Dual 5-α reductase inhibition promotes hepatic lipid accumulation in man as a result of changes to lipid metabolism in adipose tissue and the liver

Hazlehurst Jonathan , Oprescu Andrei , Nikolaou Nikolaos , Guida Riccardo Di , Grinbergs Annabel , Davies Nigel , Flintham Robert , Armstrong Matthew , Taylor Angela , Hughes Beverly , Yu Jinglei , Hodson Leanne , Dunn Warwick , Tomlinson Jeremy

Background and aims: 5α reductase 1 and 2 (SRD5A1 (expressed in liver and adipose), SRD5A2 (expressed in liver) inactivate cortisol to 5α-dihydrocortisol in addition to their role in the generation of dihydrotestosterone and therefore regulate the tissue availability of cortisol. Dutasteride (dual SRD5A1 and SRD5A2 inhibitor) and Finasteride (selective SRD5A2 inhibitor) are commonly prescribed, but their potential metabolic effects have only recently been identified....